CD74 is a potential biomarker predicting the response to immune checkpoint blockade.

Background: Immune checkpoint blockade (ICB) has been improving the patient outcome in multiple cancer types. However, not all patients respond to ICB. Biomarkers are needed for selecting appropriate patients to receive ICB.